Prostate cancer patients with inherited BRCA2 mutations have a very aggressive disease, with higher grade, advanced stage at diagnosis and poor survival [14,15,16,17,18,19,20], making a priority the development of novel therapeutic strategies for these patients. The gene discussed is BRCA2; the disease is Familial prostate cancer.